N/A N=53

Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Bottom Line

View on ClinicalTrials.gov: NCT00549445 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2017

Primary outcome: Primary: Levels of PGP From Sputum Samples of COPD Patients Being Treated With Azithromycin. — 2.27; 5.15 ng/mL — p=0.045

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Azithromycin (Drug); Placebo (Drug)
Age: Adult, Older Adult · 40+ yrs
Sex: All
Sponsor: University of Alabama at Birmingham
Primary completion: Jul 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Levels of PGP From Sputum Samples of COPD Patients Being Treated With Azithromycin.	2.27; 5.15	0.045 sig

Summary

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease. Azithromycin, an antibiotic, may be beneficial at reducing the symptoms and severity of the disease. This study will analyze previously collected study data to evaluate the anti-inflammatory properties of azithromycin and determine how azithromycin affects the frequency and severity of COPD exacerbations.

Eligibility Criteria

Inclusion Criteria

Participating in the COPD Network Macrolide study
Clinical diagnosis of at least moderate COPD
Cigarette consumption of 10 pack years or more

Exclusion Criteria

Diagnosis of asthma
Predicted life expectancy of less than 3 years
History of hypersensitivity to macrolide antibiotics
Long-term kidney insufficiency
Long-term liver insufficiency
Prolonged QT interval
Use of medications that may prolong the QT interval

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00549445). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.